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3 ABBREVIATIONS 
 
ACN    Acetonitrile 
 
Boc2O    Di-tert-butyl dicarbonate 
 
d    Doublet 
dd    Double doublet 
ddd    Double double doublet 
ddt    Double double triplet 
dt    double triplet 
DCC    N,N-dicyclohexylcarbodiimide 
DCM    Dichloromethane 
DMAP   Dimethylaminopyridine 
DMF    Dimethylformamide    
DNA    Deoxyribonucleic acid 
 
EDCI    N-(dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
EPR    Enhanced Permeability and Retention 
 
FDA    Food and Drug Administration 
 
GABA    γ-Amino Butyric Acid 
 
HA    Hemaglutinin 
HAART   Highly Active Antiretroviral Therapy 
HIV    Human Immunodeficiency Virus 
HPLC    High Performance Liquid Chromatography 
Hz    Hertz 
 
m    Multiplet 
mM    Milli Molar 
MeOH    Methanol 
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NA    Neuraminidase    
NMR    Nuclear Magnetic Resonance 
NNRTI   Non-Nucleoside Reverse Transcriptase Inhibitor 
NRTI    Nucleoside Reverse Transcriptase Inhibitor 
 
OTV    Oseltamivir 
OTVC    Oseltamivir carboxylate 
OTVP    Oseltamivir phosphate 
 
q    quartet 
 
RP-18    Reverse Phase silica with 18 carbon chain 
RNA    Ribonucleic acid 
 
s    Singlet 
 
t    Triplet 
TCE    Trichloroethanol 
THF    Tetrahydrofurane 
tt    Triple triplet 
 
WHO    World Health Organization 
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4 SUMMARY 
 
A series of ester derivates, potential prodrugs, of the antiviral agent oseltamivir carboxylate 
(OTVC) has been attempted synthesized. The aim was to synthesize prodrugs with high 
affinity for proteins compared to OTVC and with a slower conversion to the carboxylate in 
contrast to the ethyl ester oseltamivir (OTV) which is the active substance of Tamiflu®. The 
approach to increase the binding was to esterify the active compound of (OTV), OTVC, with 
a ligand that carry a free carboxylic acid. Such a component will carry a negative charge in 
vivo and be somewhat hydrophobic, and should therefore bind to albumin. Most likely, the 
prodrug with increased protein binding will give fewer side effects than the mother 
compound, due to the fact that it is highly bound to albumin rendering the free concentration 
low. It is also possible that a passive targeting effect can be achieved. This is because there 
has been observed enhanced protein retention effect in infected tissue. 
 
Both the acid of the ligands, and the amine group of OTVC had to be protected in this 
synthesis in order to avoid side reactions. The amine was first tried protected with 
isonicotinyl. However, this synthesis proved to be troublesome. Tert - bytylcarbonate was 
therefore chosen instead. As a protection group for the acid, trichloroethanol (TCE) was 
chosen. 
 
OTV was hydrolyzed and the amine group was protected with tert – butylcarbonyl. The acid 
of the ligand was protected with TCE and esterified with the acid of the protected OTVC. Due 
to lack of time, a successful deprotection step was not achieved.  
 
There have not been published structures of neither OTV nor OTVC based on x-ray 
crystallography. It was an aim of this thesis to grow crystals of these compounds, and obtain a 
structure based on x-ray. There were obtained crystals both structures, however, they were too 
small for reliable data to be obtained. 
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5 INTRODUCTION 
 
5.1  The different types of viruses 
 
Infection by parasites is an ongoing process in all living organisms. Many of the parasites that 
infect humans make use of their own machinery to perform their reproduction and they rely 
on their host cells only for nutrients. Although they are very unpleasant guests in our body 
and cause death and destruction, the viruses are the ultimate parasites. They travel light and 
most of them carry no machinery on their own, not for replication and not for making use of 
any energy whatsoever. What they carry is information of how the host shall replicate them. 
 
 
The viruses are not considered to be living organisms since they do not satisfy the basic 
criteria of life. They are acellular and do not carry out metabolism in any form; neither 
photosynthesis, cellular respiration, nor fermentation. At the Rockefeller Institute, Wendell 
Stanley was able to isolate the first virus in 1933, and discovered that viruses can best be 
regarded as a chemical matter, rather than life since the virus precipitated as crystals from a 
solution. The precipitated tobacco mosaic virus was able to infect healthy tobacco plants. This 
showed that the precipitate was a virus, and not just a chemical derived from it (1). 
 
When a virus infects its selected host, it releases its genome in the cell. The genome is 
transcripted and translated by the cells machinery, and this produces a variety of proteins. 
This is the way the virus takes control over the host cell. “In general, replication  involves 1) 
disassembly of the infectious virus particle, 2) replication of the viral genome, 3) synthesis of 
the viral proteins by the host cell translation machinery, and 4) reassembly of  these 
components into progeny virus particles” (2) 
 
All of the genomes of viruses are covered by a protein layer, synthesized by the cells 
machinery, ordered by the viral genome. Some of the viruses are in addition packed in a lipid 
envelope that originates from the cell wall of the host. These are called enveloped viruses. 
The viruses that do not carry such a lipid envelope multiply in so large numbers that it finally 
kills the cell. The cell wall bursts (a lysis occur) and the progeny virions spread out infecting 
nearby cells. An example of a clinical manifestation of this lysis is the cold sores caused by 
herpes simplex, due to the killing of epidermal cells. The enveloped viruses, on the other 
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hand, do not kill the host cell in the releasing process. This type of viral release is called a 
budding, where the intracellular viral particle is encapsulated by a part of the outer cellular 
membrane, as shown in Figure 1 below. 
 
 
Figure 1: (A) Electron micrograph of an animal cell from which six copies of an enveloped virus are 
budding. (B) Schematic view of the envelope assembly and budding process.  The lipid bilayer is derived 
from the host cell plasma membrane. The proteins shown in green are encoded by the viral genome. 
Reprinted from (2). 
 
When the budding is complete, the progeny virus is coated with a part of the cellular 
membrane. As mentioned, the cell is not killed when the viruses leave the cell in a budding 
process, but lives on, producing new virus particles continuously. This is the reason why the 
enveloped viruses in general can cause chronic infections (2). The influenza virus is 
enveloped, however, the infection is not chronic. 
 
There are mainly 6 families of respiratory viruses: orthomyxovirus, paramyxovirus, 
picornavirus, coronavirus, adenovirus and herpesvirus. Other types of viruses are listed in 
Table 1 on page 11. 
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Table 1: An overview of some of the virus families(3, 4). 
 
Family Genome Disease 
Orthomyxovirus RNA Influenza 
Paramyxovirus RNA Measels and mumps 
Picornavirun RNA Colds, meningitis, poliomyelitis 
Coronavirus   
Adenovirus DNA Sore throat, conjunctivitis 
Herpesvirus DNA 
Chickenpox, shingels,cold sores and glandular 
fever 
Poxvirus DNA Smallpox 
Papillomavirus DNA Warts 
Rubella virus RNA German measles 
Rhabdovirus RNA Rabies 
Retrovirus RNA Like HIV causing AIDS 
Arenavirus RNA meningitis 
Hepandavirus RNA Serum hepatitis 
Rabovirus RNA Tic borne encephalitis and yellow fever 
 
 
Figure 2: Different types of viruses. Reprinted from (2). 
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5.2 Viral taxonomy 
It is not clear if all the viruses have a common origin, so a Linnaean classification, which has 
been applied for the living organisms, is not applicable for viruses. However, a logical 
classification is needed to understand viruses in detail, and how to generalize them. Schemes 
has been worked out, classifying them regarding to their basic properties. The three most 
important properties are types of genome inside the capsid (DNA or RNA, single or double 
stranded, circular or linear, single piece or segmented), protein arrangement of the capsid 
(symmetry and dimensions) and other components (enveloped virus, important enzymes). 
This is a rough classification irrespective of what type of cell the virus infects, or what disease 
it causes (5). Figure 2 on page 11 show the shape and structures of different type of viruses. 
 
5.2.1 The Baltimore scheme of virus classification 
The Baltimore scheme of virus classification, suggested by David Baltimore in 1971, is based 
on the way the viruses produce mRNA. In order to have proteins synthesized, all viruses must 
produce mRNA in some way, but viruses differ in which genome they utilize for this. Viruses 
with genome of the same sense as the mRNA, are called positive (+) sense RNA viruses, 
while those who have the opposite sense of mRNA are called negative (-) sense RNA viruses. 
This classification scheme has limitations and is used mostly for classifying RNA viruses. (5) 
In a classification scheme based on the Baltimore classification and the three basic properties 
mentioned above, the influenza virus is classified like this: Single stranded RNA virus – 
Negative sense RNA – Envelope – Helical – Segmented genome. In this class we find the 
orthomyxovirus, causing influenza. 
 
 
5.3 Influenza and avian flu 
“Influenza has long been with us; indeed, the name itself refers to the ancient belief that it was 
caused by a malign and supernatural influence. In Florence during the time of the renaissance, 
astrologers linked a curious juxtaposition of stars with an outbreak of infection in the city and 
attributed it to the ‘influence’ of the stars, hence influenza.”(6) 
 
Influenza is mainly spread through droplets as aerosols from the airways, but can also infect 
through direct contact. Viruses of influenza A and B usually cause epidemics during the 
winter. The influenza B epidemics are often limited while influenza A epidemics has a 
tendency to be pandemic. Pandemics with influenza A are seen when new subtypes of the 
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virus occur in which the population has no immunity to. There has been reported 258 human 
cases (cumulative number) of avian influenza A/(H5N1) to the WHO (World Health 
Organization). Of these cases there are 153 deaths (7), giving a death rate of 59 %. 
 
A calculation from WHO indicates that influenza gives considerable disease in 3-5 million 
people annually. It is presumed that the influenza causes casualties in 250.000 – 500.000 
people in the industrialized world alone. Even though the infection of influenza limits itself, 
there are few other diseases that inflict the society so big costs in form of absence from work 
due to illness, suffering, visit at the physicians office, hospitalization, and direct economic 
losses (8). 
 
5.3.1 Hemaglutinin and neuraminidase 
 
 
Figure 3: A model of the influenza virus.  Hemaglutinin is showed as purple "mushrooms" and 
neuraminidase as yellow spikes. 
 
 
Hemaglutinin (HA) and neuraminidase (NA) are two proteins located on the surface of the 
influenza virus as showed in Figure 3. To date, there have been identified 16 subtypes of HA 
and nine subtypes of NA from influenza A viruses in birds (9). The genome of the influenza 
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A virus consists of eight RNA molecules, and HA and NA are coded on separate RNA 
strands. This segmentation of genome facilitates the virus to transfer one subtype of HA and 
NA from one virus to another during antigenic shift (explained in section 5.3.2 on page 16). 
These two proteins are antigens recognized by the human body, and the different 
combinations of the two antigens define the particular strain of influenza. The strains are 
hence named after which subtype of antigen expressed on its surface. H is the abbreviation for 
HA and N is the abbreviation for NA e.g. H5N1 (the avian flu threatening us today), H3N2 
(the Hong Kong flu in 1968), H2N2 (the asian flu in 1957) and H1N1 (the Spanish flu in 
1918). It is only in influenza A that the numbering of HA and NA is used since there has not 
been observed such variation in the influenza B virus. 
 
 
Figure 4: HA complexes with receptors on the cell surface and the virus-receptor complexes are 
endocytosed. H+ enters the endosome through an M2 ion chanel. The low pH alters the HA in such a way 
that a fusion peptide is moved to the endosomal membrane. The fusion of the viral and endocytotic 
membrane result in the release of viral genome into the cell. Reprinted from (2). 
 
HA plays an important role in the attachment to the terminal sialic acid residues on the cell 
surface of the new host cell glycoprotein and glycolipids. In addition, HA is involved in the 
viral fusion with the cell membrane, which results in the intracellular release of the viral 
contents as outlined in Figure 4 above. 
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Figure 5: Panel A shows action of NA in the continued replication of virions in influenza infection. The 
replication is blocked by NA inhibitors (Panel B), which prevent virions from being released from the 
surface of infected cells.  Reprinted from (10) with permission from the publishing division of the 
Massachusetts Medical Society. 
 
NA is an enzyme that cleaves the terminal sialic acid residues of the cellular receptor, and 
hence is crucial for the release and spread of new progeny virions as displayed in Figure 5 
(11). In addition to be important in the release process, a study has proposed that NA in 
addition to HA is an important factor for the viral entry into the host cell (12). 
 
In the process where NA cleaves the bond between the glycoprotein and sialic acid, there is an 
intermediate step where the sialic acid is in a transition state as shown in Figure 6 on page 16. 
This intermediate transition state, which is a half-chair conformation (13), has been the basis 
for the development of inhibitors for NA. Transition state analogues are regarded as good 
templates for synthesizing new inhibitory drugs. If a mutation occurs in such a way that it 
causes drug resistance against NA inhibitors, the intermediate transition state would not fit 
either, leaving the protein nonfunctional and not virulent. This is actually the case for OTVC 
which cosely resembles the transition state of the sialic acid cleavage. Where mutations in the 
NA have occurred in a way that the IC50 of OTV is significantly increased, the virus is not 
virulent and the patients recover from the infection. 
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Figure 6: The cleavage of sialic acid from glycoprotein. The transition state is a half-chair conformation. 
 
 
5.3.2 Antigenic shift and drift 
 
When two or more strains of influenza A infect the same cell, a reassortment of genome 
(exchange of genes) may occur (14). Such reassortments may yield major genetic changes, 
and are referred to as antigenic shifts. The ability of antigenic shift has been seen in the 
influenza A only, not in the influenza B or C (5).  Minor genetic changes, on the other hand, 
are mainly due to point mutations, and are referred to as antigenic drift. The nucleic acid 
replication by the virus-encoded RNA-dependent RNA polymerase complex is relatively error 
prone, with a point mutation at about every thousand base per replication cycle (15). Due to 
Darwins theory of evolution, the natural selection favors the human influenza strains that are 
able to avoid being neutralized by antibodies from prior infection or vaccination. An infection 
of a new viral subtype (antigenic shift) can cause a pandemic outbreak such as the Asian flu 
in 1957 and the Hong Kong flu in 1968, while a reinfection of the same viral subtype with 
minor genetic changes (antigenic drift) accounts for the annual nature of flu epidemics (11). 
This also explains the reduced efficacy of influenza vaccination, since the amino acid 
sequence used in the vaccine may have changed due to the antigenic drift before the epidemic 
outbreak.  
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5.3.3 Treatment of influenza 
 
The prophylactic treatment is to vaccinate vulnerable patient groups (e.g. elderly, persons 
with chronic airway or cardiac diseases, immunocompromised, diabetics and residents in 
retirement- and nursing homes). This yields a protection of 60–90%in those who are 
vaccinated (8). However, the supplies of vaccines for mass immunization are in general 
limited due to inadequate production capabilities (14). It might also be a concern that if the 
production of vaccines is delayed, the delivery to the markets may be too late to immunize the 
intended patient groups before the onset of the epidemic.  
 
For those infected with the virus, an early treatment (within two days) with NA inhibitors will 
shorten the time of illness with 1-4 days, and reduce the frequency of complications (8).  
 
5.3.3.1 Use of antiviral agents 
OTV is indicated for treatment and prophylaxis against flu in persons older than one year. 
Zanamivir has the indication for treatment in adults and children older than 12 years. The 
indication for prophylaxis is still not approved in Norway, but is so by the FDA in the USA. 
 
A disease protecting effect has been reported for both OTV and zanamivir to be 70–90 % 
used prophylactic before or just after infection. When treatment is started within 48 hours 
after the first symptoms (fever and chills) have appeared, the duration of the disease are 
shortened with 1–2 days in average. Treatment started within the first 12 hours after onset of 
fever, shortened the duration of the disease by 3 days. No studies have so far been large 
enough to prove any mortality rate. 
 
The use of NA inhibitors are the only available treatment against H5N1 avian flu if it should 
become a pandemic influenza, since H5N1 strains has proven to be resistant to adamantanes 
(16). 
 
5.3.4 From avian flu to human influenza 
 
Influenza A viruses, with the most of the HA and NA subtypes, are carried asymptomatically 
in the gastrointestinal tract of wild birds. Although in wild birds they cause no symptoms, 
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they do cause disease in domestic birds and mammals, such as pigs and humans. Thus, it can 
be considered an avian zoonosis (11). 
 
Since the beginning of the twentieth century, only the H1, H2, and H3 subtypes of HA and N1 
and N2 subtype of NA have been associated with so stable infection in humans that they 
result in recurrent annual epidemics. However, this does not mean that the H5N1 as a 
pandemic among humans is out of the question. 
 
5.3.4.1 External mixing bowl needed or not? 
 
For a successful viral influenza infection, it is crucial for the virus HA to bind to the sialic 
acid on glycoproteins or glycolipids on the host cell surface. This receptor may consist of a 
terminal sialic acid with a 2–3 linkage [NeurAc(α2–3Gal] or a 2–6 linkage [NeurAc(α2–6Gal] 
to a penultimate galactose residue of glycoproteins or glycolipids (11). The two linkages are 
shown in Figure 5a on page 15. The tracheal epithelia of birds mainly express the 2–3 linkage 
of sialic acid, while the corresponding cells in humans express the 2–6 linkage. What is 
interesting is that the pig tracheal epithelia express both the 2–3 and the 2–6 linkage. This has 
lead to the mixing bowl theory, where the pig has to be infected by both an avian flu and a 
human influenza, where both viruses infect the same cell. When this takes place, it is possible 
that an antigenic shift occurs, with a possible outcome of an avian flu with a binding 
preference to a 2–6 linkage (the human linkage) instead of a 2–3 linkage (the avian linkage). 
This is shown in Figure 5b on page 15.These progeny viruses can infect humans and spread 
among the population resulting in a pandemic flu. Early isolates of the 1957 and 1968 
pandemics show that they have a binding preference for the 2-6 linkage, while the H5N1 still 
prefers the 2–3 linkage. This means that the feared H5N1 virus, as it exists today, mainly is a 
hazard to the birds. Although people have been killed, the virus is not a pandemic yet. 
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Figure 7: (a) Sialic acid residues can be covalently attached to galactose residues of integral glycoproteins 
and glycolipids via either 2–3 or 2–6 α linkages.  (b) Since the avian epithelial cells express only the 2-3 
linkage and the corresponding cells of humans express the 2-6 linkage, there is a barrier between the 
species. However, the epithelial cells of swine express both linkages and can be coinfected with both 
human and avian flu.  The avian virus can thus overcome the species barrier, by making a detour by pigs. 
Reprinted from (11) 
 
There is, however, posted a new theory recently that states that viruses that prefer cells with a 
2–3 linkage may infect humans directly, without the previously thought obligatory 
intermediate stage in pigs. The results showed that human lineage viruses preferentially 
infected human noncilated respiratory epithelial cells in culture, which preferentially 
expressed receptors with 2–6 sialic acid linkages. This was no surprise. What is interresting, 
is that the viruses from the avian isolates (H5N1), in contrast, preferentially bound to and 
infected the human ciliated respiratory epithelial cells. These cells are a minority among 
human respiratory epithelial cells, but still a significant number, and the surprising finding is 
that they express receptors with 2–3 linkages. These results pose that there is a possibility for 
viral reassortment (antigenic shift) at sites of respiratory epithelium where ciliated and 
nonciliated epithelial cells are adjacent, and thus using the human as the mixing bowl instead 
of the pig (17). 
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5.3.5 Avian influenza drug resistance 
 
The H5N1 avian influenza has shown to be able to rapidly develop resistance to the 
adamantanes (10). There are naturally occurring strains of influenza in the community  
resistant to the adamantanes, but there is no evidence for such a resistance to either of the two 
NA inhibitors before their introduction to the markets (18). 
 
The NA inhibitors have proven that they to a far lesser extent provide the development of 
drug resistant strains of influenza virus than the adamantanes do. About 0.4 % of the OTV 
treated adults were host for resistant influenza virus which is somewhat higher than for 
zanamivir where no resistant virus was found (10). Children seem to host viruses that develop 
resistance to OTV at a higher rate (5.5%) than the viruses in adult hosts (19). There has also 
been reported a study where 16% of children treated with OTV carried viruses developing 
resistance, while 2% carry viruses with a mutation not resulting in resistance (20). It is a 
serious concern that children tend to host resistant strains, especially since they are important 
in the spread of influenza in the community (21). 
 
However, there has not been documented any transmission of OTV resistant virus from 
human to human. In fact, it has been demonstrated that viruses with the most common NA 
mutation (Arg292Lys, which is arginine  lysine mutation at amino acid 292) leave the 
enzyme defective, which in turn reduces the infectivity and transmissibility of the virus (22). 
This is most likely because the drug is a transition state analogue. When the drug does not fit, 
neither do the transition state of the sialic acid. 
 
For the N2 subtype of NA the observed mutations were Arg292Lys, Glu119Val, and 
Asn294Ser, which were about 104–105-fold, 500-fold and 300-fold more resistant, 
respectively, than their pre-treatment NA (20).  
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5.4 Protein binding 
 
5.4.1 Drugs and plasma proteins 
 
After the drugs have been absorbed from the gastro intestinal tract, they are transported by the 
bloodstream to other compartments of the body. If the drug is lipophilic, it has to bind to 
proteins to be transported by the bloodstream, but if the drug is easily soluble in water it needs 
no protein and can travel as a free drug. 
 
It is the free drug concentration that is the important parameter for both effect on the target 
organ and excretion from the body. The drugs bound to proteins are not available for exerting 
its function to the intended target, nor are they available for excretion. The kidneys only 
filtrate what is dissolved in blood, so what is bound to proteins easily pass the renal 
glomerular filtration entering the systemic circulation again. Not only do they avoid renal 
excretion but also the hepatic conjugations, since the protein bound drugs are not exposed to 
liver enzymes. There are however exceptions; both the liver and the kidneys have active 
transporters that effectively can remove compounds bound to proteins (23, 24). However, it is 
assumed that this is not the case for the prodrugs synthesized in this work.  
 
As the protein bound drugs avoid both the renal and hepatic excretion, it stays longer in the 
bloodstream, resulting in an increased duration of effect, due to the depot effect of albumin 
bound prodrug. Thus, increased protein binding will result in prolonged presence of the drug 
in blood. You can say that the protein functions as a depot for the drug (25).  
 
The distribution volume (Vd) is defined as “the volume 
of fluid required to contain the total amount, Q, of drug 
in the body at the same concentration as that present in 
plasma, Cp” (3). Drugs that bind outside the plasma 
compartment, or enter the body fat, increase the Vd 
beyond the total body fluid, which is about 0.55 l/Kg. A 
high Vd tells us that the drug penetrates to the tissue 
compartment, while a drug with low Vd is confined to 
plasma compartment and may be highly protein bound. 
 
Vd= Cp
Q
 
 
Formula 1: The distribution 
volume (Vd) is the ratio of total 
amount of drug and concentration 
of free drug in plasma. 
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The disadvantage of a highly protein bounded drug is the risk of interaction with other drugs. 
If other drugs or ligands bind to the same site, the drug with the lowest affinity will be 
displaced from the protein. This will cause an extraordinary increase of free drug, which may 
lead to intoxication. However, this happens rarely and only with drugs with a small 
therapeutic index and with drugs with a relatively high dosage. 
5.4.2 Albumin 
 
The most abundant protein in plasma is albumin, which accounts for about 60% of all proteins 
in this body compartment. The albumin binds a broad spectrum of compounds, and those who 
are strongest bound are hydrophobic organic anions of medium size, long chain fatty acids 
(LCFA) of 100 – 600 Da, hematin and bilirubin. Examples of compounds that are less 
strongly bound are tryptophan and ascorbic acid (26). 
 
The “assignment” of albumin in plasma is to solubilise and transport compounds that 
otherwise are insoluble in water. Since the protein is in abundance compared to its ligands, it 
can also function as a depot as mentioned above, making the ligands available in plasma way 
beyond their solubility. Another function of albumin is to cleanse the plasma from toxins, 
capturing them and transport them to the liver or kidney for excretion. 
 
Albumin tends to bind hydrophobic compounds carrying a negative charge well (25, 27). 
Among the broad spectrum of cargo the albumin can carry, the most important ones are the 
endogenous substances, which bind to an adaptable hydrophobic pocket with a positive 
charge situated at a lysyl or arginyl residue. The negative charge at the ligand forms a strong 
salt bond with the positive charge from the albumin (26). 
 
In 1975, Sudlow described to binding sites at albumin that were named Sudlow’s site I and II. 
In this text they are referred to as site I and site II. Many other sites have been described since. 
Examples of ligands that bind to site I are salicylate, sulphonamides and bilirubin, while 
tryptophan, thyroxine and octanoate binds to site II. In addition, drugs that are aromatic in 
nature can also bind to site II. This site can also catalytically hydrolyse various esters. 
Most of the ligands that bind have one or a few primary binding sites, to which it binds well, 
in addition to other binding sites with lower affinity. It has been demonstrated that lipids 
lacking the carboxyl group bind less tightly to albumin than the LCFA. 
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LCFAs, which are fatty acids with carbon chains from C16 to C20, and medium chain fatty 
acids (MCFA) have several binding sites in albumin. LCFAs, however, seem to have their 
primary binding site at site II, and MCFAs at site I. The fact that LCFAs primarily bind to site 
II may pose problems regarding therapy with drugs with the same primary binding site, since 
LCFAs may displace the drug and cause unpredictable plasma concentrations of the drug. It is 
hard to predict which patients this will concern, since there can be great inter- and intra 
individually differences (26). 
 
MacKichan has reviewed the problems with drug displacement interactions due to protein 
binding. There are two ways of displacing a drug from a protein, competitive and non-
competitive. In the former case, there is a competition between the displacer and the drug for 
the same binding site, while in the case of a non-competitive inhibition, the displacer alters 
the tertiary conformation of the protein, making the binding site unrecognisable for the drug. 
He states four general requirements that must be fulfilled for a drug displacement to be 
clinically relevant: 
 
• The displaced drug must be highly bound, so that a given decrease in its bound 
fraction will result in a large percentage increase in its unbound fraction. 
• The displacer and the displaced drug must share a common binding site (if 
competitive) or a common protein (if non-competitive). 
• For true competition to occur, the binding sites must be limited in number, hence, the 
molar concentration of the displacer must approach the concentration of protein 
binding sites. 
• The free concentration of the displacer must be higher than that of the displaced drug 
and/or the binding site affinity for the displacer must be higher then that for the 
displaced drug.  
 
He concluded that “although drug displacement is common and sometimes predictable, it 
alone is rarely responsible for observations of adverse drug interactions” (28).  
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5.4.3 The reasons for making a protein binding prodrug 
 
 
Figure 8: The pro moiety binds to albumin and is temporarily linked to the drug moiety. When the 
linkage is broken, the drug is a free drug in plasma. 
 
There are mainly two advantages with protein bounded drugs. First, as mentioned above, the 
proteins function as a depot for protein binding drugs, due to the depot effect. This means that 
a frequent dosage is unnecessary. This will significantly ease a higher compliance of drug 
therapy, which is especially important in HIV patients. Secondly, there has been discovered 
that cancer tissue has an enhanced permeability and retention effect (EPR), where proteins 
and lipids are restrained by the tissue. The mechanisms for this effect are “extensive 
aniogenesis and hence hypervasculature, defective vascular architecture, impaired lymphatic 
drainage/recovery system, and greatly increased production of a number of permeability 
mediators” (29). This enhanced vascular permeability has also been seen in infected tissues 
with plasma proteins, macro molecules and lipid particles leaking into the interstitial space 
(29). The EPR concept is now regarded the “gold standard” in the design of new anti cancer 
agents (30). It has been discovered that mice infected with influenza virus carry out excessive 
production of superoxide and NO, two of the permeability mediators that result in the EPR 
effect. This indicates that an EPR effect can occur during an influenza infection. 
This EPR characteristic is possible to exploit in drug targeting. This has already been done by 
Kratz et. al., who synthesized a prodrug of doxorubicin, which is the chemotherapeutic agent 
against several types of cancer, covalently bound to a thiol group at albumin. The prodrug is 
proposed to be released in close proximity to the cancer cell, due to the acidic environment 
and the acid sensitive bond between doxorubicin and albumin (31). 
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If the prodrug is synthesized by extracting albumin in large scale and linking it to the 
doxorubicin molecule, there will most likely be a problem with an unwanted immune 
response. Making the drug in situ in a hospital, linking the drug to the patients own albumin 
might circumvent this problem. However, it is very unpractical and takes a lot of resources to 
do the extraction, purification and finally the linking of drug to albumin ex vivo. 
 
5.5 The prodrug concept 
 
There are several ways of dealing with poor drug delivery characteristics. Some drug delivery 
problems can be circumvented by dosage form design. Another approach is to make a new 
analog of the parent drug. Designing a new drug with the desired physiochemical properties, 
the pharmacological profile may change, which results in series of new time consuming and 
expensive biological testing. Delivery characteristics are often changed appropriately by 
synthesizing a bio reversible chemical derivate. This is called the prodrug approach. 
 
The concept of making bioreversible drugs based on other drugs that already are known to be 
effective has lately become a popular way of doing drug research. In fact, there was a 2000 % 
increase in new prodrug patents from 1993 to 2002 in the USA. New cancer drugs accounts 
for 37 % of these patents. In 2001 an 2002, 14 % of all drugs approved by the FDA were 
prodrugs (32). 
 
The prodrug in itself has no effect pharmacologically, but after degradation in vivo it is split 
into an active drug moiety (the parent drug) and an inert pro moiety. This provides a number 
of advantages. First, the physiochemical and pharmacological properties are transient, 
allowing the prodrug to have favorable properties, which the parent drug lacks, till the in vivo 
cleavage. This means that it is possible to temporarily mask the undesirable physiochemical 
properties of the parent drug. Secondly, synthesizing different chemical derivatives of the 
same drug allows the prodrug to have a broad spectrum of transient physiochemical properties 
(33). Thus you can pick and choose the properties you want. 
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According to Claus S. Larsen and Jesper Østergaard, rational prodrug design must consist of 
three basic steps (33): 
• Identification of the drug delivery problem 
• Identification of the physiochemical properties required for maximum efficacy or 
delivery 
• Selection of a transport moiety providing a prodrug derivate exhibiting the proper 
physiochemical characteristics and which can be cleaved in the desired biological 
compartment  
 
Dissolution and transport processes are the two processes which largely determine how much 
of the drug reaching its target receptors. These processes primarily depende on lipophilicity 
and aqueous solubility. The transport rate of a drug is usually enhanced by making the 
prodrug a more lipophilic substance. Initially the transport rate over membranes is increased 
exponentially with increased lipophilicity. However, this is only to a certain point. Drugs or 
prodrugs with too high lipophilicities often have low bioavailability due to the poor aqueous 
solubility. On the other hand, drugs that are too hydrophilic, often exhibit poor transport 
properties. Therefor, it is apparent that the drug or prodrug must possess both of the 
physiochemical properties to a certain degree (33). 
 
Reasons for making a prodrug (33): 
• Drug targeting 
• Stabilization of the drug 
• Enhancement of drug solubility 
• Improvement of circulation life time and hence extended duration of action 
 
Drug targeting is the main reason for making prodrug of OTV. This is due to the enhanced 
protein binding and the EPR effect in inflamed tissue, which is discussed in section 5.4.3 on 
page 24. Increased protein binding also results in extended duration of action due to the depot 
effect of decreased renal filtration and hepatic conjugation as outlined in section 5.4.1 on page 
21. 
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5.6 Other antiviral agents 
Since the viruses are intracellular parasites utilizing the hosts machinery for replication, it is 
difficult to find a chemical that halts or slows the viral infection. Chemical agents that inhibit 
both the host and the virus are not a good choice of therapy, due to the adverse effect they 
might cause. The best approach is to identify the unique functions of the virus, which differ 
significantly from the functions of the host, and then block this critical step in its life cycle 
(5). Table 2 lists some targets for antiviral drugs and examples of available medicines in each 
group. 
 
Table 2: Some targets for antiviral drugs. Reprinted and modified from (5). 
 
Step in virus life cycle targeted Molecular target of 
inhibitor 
Example 
Virus attachment and entry Surface protein-receptor 
interaction 
Receptor analogues, fusion 
protein amantadine 
DNA virus genome replication Viral DNA polymerase Acyclovir 
RNA virus genome replication Viral RNA replicase (Theoretical) 
Retrovirus – reverse transcription Reverse transcriptase AZT, ddC, ddl 
Retrovirus – integration Integrase (Theoretical) 
Viral transcriptional regulation HIV tat (Theoretical) 
Viral mRNA posttranscriptional 
processing (splicing) 
HIV rev (Theoretical) 
Virion assembly Viral protease Protease inhibitors 
(ritonavir, atazanavir) 
Virion assembly Capsid protein – protein 
interactions, budding 
Rimantadine, protease 
inhibitors 
 
 
5.6.1 Reverse transcriptase inhibitors and protease inhibitors 
 
These two classes of antiviral agents are the most important in treating an infection of HIV. 
Reverse transcriptase is an enzyme that makes a double stranded DNA copy of the viral RNA 
after the entry into the cell. This DNA then enters the cell nucleus where it integrates with the 
host DNA. When the hosts DNA is transcribed, a provirus mRNA is transcribed at the same 
time. The host ribosomes translate the provirus mRNA into biochemically inert polypeptides. 
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The enzyme protease cleaves the polypeptides at the appropriate places to produce structural 
and functional proteins. Since protease does not occur in the host, it is a good drug target. An 
inhibition of both of the enzymes reverse transcriptase and protease is a critical loss for the 
viral replication. However, these inhibitions do not kill the virus, since it remains dormant in 
the host nucleus, incorporated into its DNA. 
 
The reverse transcriptase inhibitors are divided in two groups; nucleoside reverse 
transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI). 
The NRTIs are converted by the host cell enzymes to the active compounds by 
phosphorylation. These compounds compete with the substrates for reverse transcriptase and 
the incorporation of the compound results in the termination of the growing viral DNA chain. 
There are currently available 6 drugs in the NRTI class. 
The NNRTIs are no substrate for the enzyme, but binds near the catalytic site denaturating the 
protein. There are currently available two drugs NNRTIs. 
 
The best treatment is a combination of several drugs, known as highly active antiretroviral 
therapy (HAART), which consists of a cocktail of some of the drugs mentioned above. A 
typical HAART combination would consist of two NRTI with either a NNRTI or one or two 
protease inhibitors (3). 
 
5.6.2 Acyclovir and valacyclovir 
 
Acycloguanosine (prescribed under the name acyclovir) was the first nucleoside analogue that 
was a chain terminating inhibitor. After acycloguanosine is transported into the cell and 
triphosphorylated, it is utilized as a substrate for the herpes virus DNA polymerase. The drug 
lacks the 3’OH group, which results in the termination the growing DNA chain. The herpes 
virus encodes a protein called thymidine kinase (TK), which is required for the first 
phosphorylation of acycloguanosine. The drug will inhibit the viral DNA polymerase about 
10 times more efficiently than the corresponding cellular enzyme. However, since the 
activation of the drug requires a viral enzyme, it is non-toxic to uninfected cells (5). 
5.6.3 Zanamivir 
Like OTV, zanamivir is an inhibitor of NA, and inhibits the spread of progeny virions from 
the infected cell. Zanamivir binds to NA close to its active site, inhibiting the natural 
substrate, sialic acid, isosterically from binding to the enzyme (13). If an outbreak of H5N1 
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pandemic influenza should occur, the only possibility for treatment and prophylaxis is the use 
of either zanamivir or OTV (16). Due to poor bioavailability orally, the drug is administrated 
pulmonary as a dry powder. Since it is easier to swallow a mixture or a capsule than fumble 
with an inhalator, Tamiflu (OTV) has reached higher sales than Relenza (zanamivir). An 
inhalation of zanamivir could pose a problem for a patient suffering from some of the 
respiratory symptoms of influenza (34).  
5.6.4 Adamantanes 
This group consists of two drugs; amantadine 
and rimantadine (Figure 9), none of them are 
on the marked in Norway. Both are used 
against influenza A. After the HA has bound 
to the sialic acid and the virus has undergone 
an endocytosis, the pH lowers to around 5. At 
this pH the membrane of the enveloped virus 
undergoes a fusion with the viral membrane, 
resulting in the entry of the viral 
nucleocapside (5).  The adamantanes work by 
interfering with viral uncoating inside the cell. 
The drug is a basic primary amine that inhibits 
the M2 ion chanel that is responsible for the 
acidification of the resulting endosome after 
viral entry (35). In this way, the adamantanes will counteract the acidification that is crucial 
for the complete viral entry. 
 
“[The adamantanes] are effective only against influenza A and are associated with several 
toxic effects and with rapid emergence of drug-resistant variants.”(10) Isolates from the 
adamantane-resistant strains have shown to be genetically stable. They are as pathogen as the 
wild type influenza, and can be transmitted between people. These characteristics have 
limited the use of adamantanes (10). This is probably why the adamantanes is not registered 
in Norway. In fact, the avian H5N1 from 2004 has shown to be resistant to adamantanes (16) 
 
 
 
 
NH2
Amantadine
NH2
Rimantadine
The adamantanes
 
Figure 9 The chemical structure of the 
adamantanes 
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5.7 Oseltamivir and its new successor 
 
OTV is marketed in Norway as Tamiflu®, and has been approved by the Norwegian 
Medicines Agency to treat influenza in infected persons over one year of age. The treatment 
has to be started within 48 hours after the first symptoms appear, but is more effective the 
earlier the treatment begins. 
It has been shown higher virulence among recent isolated H5N1 viruses reducing the efficacy 
of NA inhibitors. OTV in a higher daily dose and a longer duration of treatment has improved 
the survival of mice (36). This finding suggests that a higher dose of OTV may be necessary 
for human avian influenza than what currently is recommended. However, more research in 
this field is needed. 
 
5.7.1 The development of oseltamivir 
 
The development of this drug is a good example of how to make a new chemical entity based 
on rational information available from the crystal structure of NA and the complex with its 
inhibitors. 
The structure of zanamivir is a half-chair conformation, and thus is almost flat. This gives the 
substituents of the ring an almost equatorial orientation (Figure 6 on page 15). There have 
been attempts to synthesize aromatic analogues of sialic acid, which were thought to have 
inhibitory effect on NA. Although the aromatic compounds showed lower inhibitory activity 
than zanamivir Figure 10 on page 30), this work has given us the knowledge that the 
substituents of the ring cannot be totally equatorial. This proves that a good inhibitor must 
comply with the strict demands of the shallow binding pocket of the influenza NA (37). 
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Figure 10: The inhibitory effect of two aromatic compounds on the NA enzyme. 
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A dissertation has recently confirmed these results. Other aromatic inhibitors was synthesized 
and evaluated for a Ph. D. degree, and they all showed IC50 values higher than OTV (38). 
Both the amino group (as in OTV) and the guanindino group (as in zanamivir) in4-position 
on the structure on the right (Figure 11) forms salt bridges with Glu119, but only the 
guanidine group provides the molecule poor 
bioavailability and rapid excretion.  These 
properties rule out the drug from being 
administered orally, as is the case for 
zanamivir. 
 
An idea of locating the double bond in the 
structure on the same spot as in the 
transition state has been of great value in the 
development of the new NA inhibitor. As a 
template, it was used a carbocyclic ring 
instead of the dihydropyran ring of the 
Neu5Ac2en system. The carbocyclic ring is 
chemically more stable than the 
dihydropyran ring and is easier to modify 
for antiviral optimization. This ring has 
another numbering than Neu5Ac2en due to 
another localisation of the double bond 
(Figure 12 to the right), which structurally 
has a closer resemblance with the sialic acid 
transitionstate during the hydrolysis in the 
nuraminidase. (Figure 6 on page 16). This resemblance has proven to be essential regarding 
NA inhibitory activity (39). When a lipohilic group was attached to the carbon in C3 position 
in the carbocyclic ring, the NA inhibitory activity increased, indicating that there is a 
lipophilic pocket in the glycerol binding site of the enzyme. This was confirmed by x-ray 
crystallography (39). 
It was discovered that the C7 hydroxyl does not interact with any amino acids in the active 
site of NA (40), which lead to the conclusion that this group could be eliminated from the 
structure. As a matter of fact, there is a hydrophobic pocket. 
The double bond in the sialic acid transition state is polarized and electron deficient. 
Replacing the C7 carbon with an oxygen atom, will further contribute to the mimic of the 
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Figure 11: A guanidino group result in poor bioavailability and 
rapid excretion. 
 
OH
O
R
HN
O
NH2
1
2
3
5
64
 
Figure 12: The numbering on the carbocyclic template. 
Note that the double bond is located in a way that it  
mimics the sialic acid transition state. 
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transition state since the oxygen will “reduce the electron density of the double bond via the 
σ bond electronegative effect” (39). A crystallographic study where OTVC were bound to the 
NA (as shown in Figure 13) showed that the carboxylate group is surrounded by tree arginyl 
residues and the C4 hydroxyl group (which is substituted amino group in OTV and guanidine 
group in zanamivir) were placed is a pocket with the highly conserved residues Glu 119 and 
Glu 227. There was also a hydrogen bonding between the protein and both the amide 
nitrogen and carbonyl oxygen at the N-acetyl group located in the C5 position, while the 
methyl group was seated on a hydrophobic patch (39).  
 
Figure 13: The interactions of OTV in the NA enzyme. Reprinted from (26) 
 
There has been performed an experiment on 
introducing lipophilic substituents (Cl, 
SCH3, and CH3) in the C2 position (Figure 
14) and the inhibitory characteristics were 
investigated. All three compounds proved to 
be poor inhibitors of NA due to the IC50 
values of 3100, 3400, 2300 nM respectively. 
This result indicates that the hydrophobic 
pocket at this place in the enzyme has a 
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Figure 14: The structure of the lipophilic C2 analouges. 
Reprinted from (41) 
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limited space that does not allow for other 
atoms than hydrogen to bind (41). 
The backbone of the glycerol of sialic acid interacts with the hydrophobic Arg 224. This was 
the reason for the search for the optimum lipophilic analogues for the C3 side chain. Several 
structures were synthesized with such substituents in the C3 position, and analyzed with 
respect to the IC50 values shown in Table 3 below (39). 
 
 
Table 3: The IC50 values for the various lipophilic substituents is C3 position. Reprinted with 
modifications from (39). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
The results as displayed in Table 3 above show an increasing affinity to the enzyme when the 
aliphatic carbon chain expands up to n-propyl, but further expansion decreases the affinity. 
Geometry also seem to be of importance, since branching of the α carbon, as in OTV, yields 
an IC50 of 1 nM, while branching of the β carbon gives an IC50 of 200 nM. The size of the 
branching is also an important characteristic as the 4-heptyl substituent is a weaker (IC50=16) 
inhibitor than the 3-pentyl substituent is with an IC50 of 1 (39). 
R IC50 (nM) 
H 6300 
CH3 3700 
CH3CH2 2000 
CH3CH2CH2 180 
CH3CH2CH2CH2 300 
(CH3)2CHCH2 200 
CH3CH2(CH3)CH* (R-isomer) 10 
CH3CH2(CH3)CH* (S-isomer) 9 
(CH3CH2)2CH 1 
(CH3CH2CH2)2CH 16 
COOHRO
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NH2
O
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Figure 15: The chemical structure of sialic acid (the substrate for NA), its transition state inside NA and 
the NA inhibitors OTVC and zanamivir. 
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6 AIM OF THE THESIS 
6.1 Main aim 
The main aim of this study is to synthesize new novel compounds that are prodrugs of OTVC, 
with increased protein binding compared to the parent drug. The novel prodrugs should also 
have a slower conversion rate to OTVC than OTC. 
 
6.2 Sub aims 
 
6.2.1 Synthesis strategy 
 
A rational strategy for the synthesis shall be worked out. The synthesis shall end with a novel 
prodrug that is thought to exhibit higher protein binding than the parent compound. 
 
6.2.2 Selection of pro moieties 
 
A series of pro moieties with slightly different chemical structures shall be selected. The 
structure should have a negative charge in form of a carboxylic acid in order to bind to 
albumin. 
 
6.2.3 Crystallographical studies 
 
Crystals of OTV and OTVC shall be grown, and x-ray structure shall be solved. 
 
6.2.4 Albumin binding 
 
When the syntheses of the prodrugs are done, the binding to human serum albumin shall be 
carried out. The albumin binding of the prodrug shall be related to the corresponding results 
from OTV and OTVC. Stability to esterase shall also be determined. 
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7 RESULTS AND DISCUSSION 
7.1 Synthesis 
 
7.1.1 Background 
 
A search on SciFinder for other synthesized carboxylic acid esters of OTV revealed that there 
was much work left to do in this area. There has been described a total of 7 esters based on 
the OTV scaffold. (See Figure 16 below) 
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Figure 16: The syntesized carboxylic acid ester structures based on the OTV scaffold. 
 
The prodrugs synthesized in Figure 16 above will result in increased protein binding due to 
increased lipophilicity. However, this results in decreased water solubility, and hence the 
prodrug might be difficult to formulate for oral administration. 
 
By introducing a carboxylic acid group to the pro moiety, the water solubility increases, 
which facilitates the oral drug formulation. In addition, the protein binding may also increase 
due to the cationic charges on the albumin as discussed in section 5.4.2 on page 22. 
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Based on the result from the structure search, we can conclude that this is an unexplored area 
that needs to be examined. 
 
7.1.2 Synthesis strategy 
 
The overall synthesis strategy was to hydrolyze the present ester on OTV, and add a new 
ligand by esterification. The problem with the esterification in OTVC is that the amino group 
can react with a carboxylic acid on a neighbor OTVC, producing an amide linked dimer or 
even a polymer. Thus, the amino should be protected to ensure that the carboxylic acid reacts 
with the alcohol only. 
 
Generally, purification is easier when the molecule has only an acid or only an amine. If the 
molecule has both groups, one of them is always charged, thus making the purification 
difficult. Therefore, it was decided that the amine group should be protected before the 
hydrolysis to avoid the possible troublesome purification. 
 
The pro moiety of the prodrug, the ligand, contains an acid group that is supposed to interact 
with the cations of albumin (see section 5.4.2 on page 22), but also an alcohol group that is 
supposed to be linked by an ester bond to the active substance, OTVC. The problem is that 
the alcohol can react with the acid of a neighboring ligand, resulting in a ligand dimer, or 
even polyester of the ligand. To circumvent this problem, the acid of the ligand should be 
protected in the synthesis. 
 
As a protection group for the amine, isonicotinyl was thought to be a good choice. The 
isonicotinyl group is described to be an especially stabile carbamate protecting group and 
might not be deprotected during the acidic hydrolysis of the ester. The deprotection of the 
isonicotinyl group is done with acid in the presence of zinc. However, this synthesis proved to 
be troublesome. This is discussed in section 7.2.7 on page 51. 
 
Since the conditions for the deprotection of the amine is acid in the presence of zinc dust, it 
would be advantageous with a protection group for the acid of the ligand that is deprotected 
under the same conditions. In this way, the deprotection can be performed in one step of 
synthesis. TCE exhibit this property, and was therefore chosen. 
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Since the isonicotinyl synthesis proved to be difficult, an alternative synthesis was needed. 
Protection with Boc cannot be done before the hydrolysis since the group is labile under 
acidic conditions. However, the protection could be done after the acidic hydrolysis, with the 
purification in a later step of the synthesis. See Figure 18. The deprotection of Boc are by 
several described in the literature to be performed under various acidic conditions (42-44). 
 
In order to deprotect both protection groups at the same time, tert butyl alcohol could be the 
protection group for the acid. Tert butyl alcohol is deprotected under moderately acidic 
conditions (44). However, at the time where it was discovered that the synthesis of 
isonicotinyl protected OTV was troublesome, most of the TCE protected ligands were already 
synthesized. Using acidic conditions in the presence of Zn dust will deprotect the TCE, 
however Boc will most likely also be deprotected although the presence of Zn is unnecessary. 
 
Although Woodward et. al. utilized 90% acetic acid to deprotect TCE in their cephalosporin 
synthesis (45), it might be feasible to use 100% acetic acid to reduce the risk of nucleophilic 
attacks of H2O on the ester bond between the drug and the pro moiety. With concentrated 
acetic acid the mechanism in Figure 17 below will not be able to proceed due to the lack of 
water. 
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Figure 17: The reaction mechanism for acidic ester hydrolysis. 
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7.1.3 The hydrolysis of oseltamivir 
 
In order to synthesize a new prodrug of OTV, the present ester has to be removed by e.g. 
hydrolysis. There are described basic hydrolysis of OTV in the literature (41), however, the 
initial experiments started with testing out acidic hydrolysis, and these results were found 
 
Figure 18: The final overall synthesis scheme for the synthesis of the new protein binding 
prodrug. The synthesis involves hydrolysis of OTV, protection of ligand and OTVC, 
esterification of protected ligand with protected OTVC, and deprotection to produce a 
new prodrug. 
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satisfactory. The mechanism for acid catalyzed ester hydrolysis is lined out in Figure 17 on 
page 38. 
 
Previously, there has been performed a study on the degradation pathways for OTV (46), 
where Oliyai et. al. stated that the degradation can follow the pathways of N,N-acyl migration 
and/or ester hydrolysis as described in Figure 19 below. 
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Figure 19: The decomposition pathways for OTV. Reprinted from (46). 
 
The N,N acyl migration is unlikely to occur due to the trans position of the two nitrogen 
atoms involved. As shown in Figure 20 on page 41, there is great distance between the amine 
nitrogen (the turquoise atom marked [1]) and the carbon it is supposed to react with (the 
turquoise atom marked [2]). This distance was measured to be 2.95 Å, which is a long 
distance for a reaction to occur. The angles and distances of the bonds in the structure was 
optimized in Chem Draw 3D 10.0, and copied to Gauss View 3.07, where the measurement of 
the distance was performed. 
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For the electrons at the amine nitrogen to 
attack the acyl carbon, there has to be great 
movement in the structure, which requires 
energy. This energy can be provided as 
heat, as was the case for Oliyai et. al. (46).  
They performed their experiments at 70°C, 
while the reaction in this work was allowed 
to proceed in room temperature. It is 
therefore not likely that N,N acyl migration 
has occurred.  
Figure 20: Amide and amine groups are located in a  
trans position to each other. Carbon atoms are 
marked grey, hydrogens are white, oxygens are red, 
amide nitrogen is blue, and the amine nitrogen and the 
carbon atom whom it is supposed to react with is 
colored turcuoise. 
 
Although N,N acyl migration is doubtful to happen, addition of HCl to the double bond might 
occur. As shown in Figure 21 below, HCl is added in such a manner that the halide binds to 
the carbon with most carbon substituents. This is due to the ability to stabilize the carbocation 
on the carbon that is not protonated. The positive charge on the less substituted carbon is less 
stable and therefore not formed. This is called the Markovnikov’s rule (47). 
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Figure 21: Demonstration of the Markovnikov's rule. The less substituted carbocation is less stable, and 
hence not formed. Reprinted from (47). It is also possible for the electrons from water to attack the 
carbocation, resulting in an alcohol instead of the chlorine as shown in the figure. 
 
In the case of degradation due to addition of HCl to the double bond, the degradation product 
will be hard to detect utilizing an ultraviolet (UV) detector. Eliminating the conjugated 
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double bond from the structure gives the 
compound significantly decreased molar 
absorbtivity. There are chromophores left 
in the structure (the C=O double bonds), 
however, the molar absorbtivity of C=C 
double bonds conjugated with C=O are 
about 1.000 times higher due to an 
electronic transition with low probability 
of occurrence (47). 
The problem with “invisible” substances 
could be overcome by using LC-MS, 
however, such an instrument was not 
available when these experiments were 
carried out. 
 
Hydrolysis of the amide catalysed by H2O and acid might also occur. Unlike amines, the C-N 
bond can easily be split because of the adjacent C=O bond (43). The reaction mechanism is 
outlined in Figure 23 below. The resulting products are an acid and an amine. On the contrary 
to the addition over the double bond, the decomposition product of the amide hydrolysis is 
visible in UV. The amides contribution for the molecule to be a chromphore is negligible as 
mentioned above. 
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Figure 23: The reaction mechanism for acid catalysed amide hydrolysis. Reprinted from (48). 
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Figure 22: The degradation product after addition of 
HCl to the double bond. Due to the Markovnikov's 
rule, the chlorine atom is placed at the more 
substituated carbon atom. 
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In this work, it was performed experiments where the acid catalyzed hydrolysis were done 
with three concentrations of hydrochloric acid; 15 %, 25 % and 32 %. As seen in Figure 24 
below the formation of OTVC in 15 % HCl is lower than in 25 % HCl. In 32 % HCl the 
formation of the impurity has increased, but OTVC is at the same level as in 25 % HCl. 
 
Figure 24: The effect of HCl concentration on hydrolysis of OTV. The UV absorbance was measured at 
230 nm with the method method 1. 
 
However, it is important to note that in this experiment the separation and analysis were done 
by high performance liquid chromatography (HPLC) with an ultraviolet (UV) detector. One 
of the proposed decomposing products is hardly visible in the UV and is therefore not 
detected. These results show only the relative concentrations of OTV, OTVC and impurity. 
However, since the yield of OTVC corresponded to the relative UV absorbances in the 
chromatogram, it was concluded that there are no “invisible” impurities are negligable. 
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7.2 Synthesis of protected ligands 
 
Ligands with acid and alcohol moiety were treated with excess of TCE in the presence of p-
toluene sulphonic acid dissolved in toluene and refluxed in a dean stark trap. TCE was present 
in excess to minimize the risk for polymerization of the ligand. This resulted in a TCE ester 
that works as protection for the acid.  
 
7.2.1  The carbodiimide coupling reagents 
 
In this thesis, two of the carbodiimide 
coupling reagents have been used, namely 
EDCI and DCC. The differences between 
them are the R groups on each of the 
nitrogen atoms. However, both utilize the 
same reaction mechanism. EDCI is water 
soluble and can easily be removed by 
extraction. DCC is lipophilic and must be 
removed by flash chromatography or 
preparative HPLC. Or, if the reaction is 
performed in e.g. dichloromethane (DCM) 
or tetrahydrofurane (THF) dicyclohexyl urea 
can be filtrated off from the reaction 
mixture. 
 
Both coupling reagents are activating carboxylic acids in order to react easisy with a 
nucleophile. The optimum pH for EDCI has been described in an article to be 7.5 (49). At 
this pH, one of the nitrogen atoms are protonated. This protonation is essential for the 
activation to take place. The electrons of the acid (nucleophile) that is to be activated, attack 
the carbodiimide carbon (electrophile). The electron withdrawal effect of the carbodiimide 
renders the carbon of the acid more electrophil. In this way, it is easier for the nucleophile to 
attack the carbonyl carbon. The nucleophile can be e.g. alcohol or amine, producing ester and 
amide respectively. The mechanism for the reaction with an alcohol is outlined in Figure 26 
on page 45. 
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Figure 25: The structure of EDCI and DCC 
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Figure 26: The mechanism of the carbodiimide coupling reagents. As described in this figure, the 
nucleophile is an alcohol, giving an ester product. However, if the nucleophile is an amine, the product is 
an amide.  
 
7.2.2 Synthesis of 2,2,2.trichloroethyl 2-(4-
(hydroxymethyl)phenyl)propanoate 
 
It was tried to replace the bromine with a hydroxyl group at the commercially available 
precursor, and then protect the acid group with TCE. This is a new compound that has not 
been described in the literature before. 
 
Tracing the reaction has shown that 20 minutes should be sufficient reaction time. 
Neutralization was done with HCl, but has also been done with formic acid in other attempts 
of the synthesis. In other attempts of this synthesis, purification was tried with extraction from 
aqueous HCOOH saturated with NaCl and Na2SO4 to DCM. However this was not successful.   
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13C nuclear magnetic resonance (NMR) shows two peaks that refer to carbonyl carbons. The 
highest carbonyl peak, 179.1 ppm, might correlate to an acid or ester. However, the lowes 
carbonyl peak, 162.9 ppm, seem to correlate to ArCOOC (50). Methanol (MeOH) was used in 
the synthesis and evaporated. However, it is possible that the residue contained traces of 
MeOH, which may have been a part of an oxidation reaction, producing a methanoic ester. 1H 
NMR does not show any peaks near the expected singlet at about 4.61 ppm (predicted by 
Chem Draw Ultra 10.0) that should have correlated to the two protons α to the OH and Ar. 
This also indicates that there has been an oxidation.  
 
The 1H NMR showed a multiplet at 7.09 ppm. This indicates that the protons are aromatic, 
however, there should be four of them. The integral of 7 indicates that there are some 
aromatic impurities. These might be impurities of p-toluene sulphonic acid in almost one 
equivalent. Some of the signals from 13C NMR might be due to this impurity.  
 
7.2.3 Synthesis of 2,2,2-trichloroethyl 4-hydroxybenzoate 
 
The extraction was done to remove residues of p-toluene sulphonic acid. To purify the 
compound, the residue was dissolved in THF and mixed with RP-18, the column material in 
HPLC. Evaporating the THF resulted in adsorption to the particles of the material. 
Purification was performed by applying the column material to a pre-column on preparative 
HPLC. This purification method was chosen due to the large amount of residue to purify 
(8.88 g)   
 
As the esterification reaction proceeds, water is produced. Since water has higher density that 
toluene, it is trapped in the dean stark trap. A figure of this equipment is shown in Figure 34 
on page 63. A water free system is an advantage in order to avoid nucleophilic attacks of 
water instead of TCE. 
 
From the 1H NMR, the signals were a singlet at 4.95 ppm that refers to the two protons at the 
TCE; a doublet at 6.92 ppm, with a coupling constant at 8.85 hertz (Hz), that refers to the two 
protons ortho to the hydroxyl group; a doublet at 8.05, with a coupling constant at 8.85 Hz, 
that refers to the two protons meta to the hydroxyl group. The proton at the hydroxyl group 
does not show in the spectrum due to deprotonation by the deuterated solvent. The shift 
values in ppm are shown by their respective atoms in Figure 27 on page 47. 
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Figure 27: The observed 1H NMR shifts values presented by their respective atoms 
 
From the 13C NMR, the signals were at 74.36 ppm that refer to the non chlorinated carbon of 
the TCE moiety; 95.12 that refer to the chlorinated carbon at the TCE moiety; 115.54 ppm 
with integral 2 that refers to the two carbons ortho to the hydroxyl group; 120.99 ppm that 
refer to the carbon atom para to the hydroxyl group; 132.60 ppm  with the integral 2 that 
refers to the two carbons meta to the hydroxyl carbon; 160.71 ppm that refer to the carbon 
with the hydroxyl group; 164.92 ppm that refer to the carbonyl carbon in the ester group. The 
shift values in ppm are shown with their respective atoms in Figure 28 below. 
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Figure 28: The observed 13C NMR shifts values presented by their respective atoms 
 
The mass spectrum showed three peaks at 266.9 m/z (100%), 268.9 m/z (95.6%), 270.9 m/z 
(8.8%) respectively. This is a typical isotope pattern from chlorine due to that about one third 
of all naturally occurring chlorine carry two extra neutrons in the nucleus. 
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7.2.4 Results of the synthesis of 2,2,2-trichloroethyl 3-hydroxybenzoate 
 
This is a new substance that has not been described in the literature before. The esterification 
was done in a dean stark trap in order to keep the reaction conditions dry. 
 
From the 1H NMR, the signals were a singlet at 4.84 ppm with integral of 2, which refers to 
the two aliphatic protons of the TCE moiety; double double doublet at 7.02 ppm with the 
coupling constants at 0.9 Hz, 2.6 Hz and 8.2 Hz which refer to the aromatic proton para to the 
ester group; triplet at 7.24 ppm with the coupling constant at 8.0 Hz, which refer to the 
aromatic proton ortho to both the hydroxyl and ester group; a double doublet at 7.50 ppm with 
the coupling constants 1.6 Hz and 2.4 Hz, which refer to the proton in para position to the 
hydroxyl group but ortho to the ester group; double triplet at 7.59 ppm with the coupling 
constants 1.2 Hz and 7.9 Hz, which refer to the proton in meta position to both the hydroxyl 
and ester group. The proton at the hydroxyl group does not show in the spectrum due to 
deprotonation by the deuterated solvent. 
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Figure 29: The observed 1H NMR shifts values presented by their respective atoms 
 
From the 13C NMR, the signals were at 74.58 ppm which refer to the non chlorinated carbon 
at the TCE moiety; 94.83 ppm which refer to the chlorinated atom at the TCE moiety; 116.60 
ppm which refer to the carbon ortho to the ester and hydroxyl group; 121.26 ppm which refer 
to the carbon para to the ester group; 122.49 ppm refer to the carbon para to the hydroxyl 
group; 129.87 ppm which refer to the carbon meta to both the hydroxyl and ester group; 
130.03 ppm which refer to the aromatic carbon attached to the ester group; 155.88 ppm which 
refer to the aromatic hydroxyl carbon; 165.10 ppm which refer to the aliphatic ester carbon. 
The shift values in ppm are shown with their respective atoms in Figure 30 on page 49. 
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Figure 30: The observed 13C NMR shifts values presented by their respective atoms 
 
 
7.2.5 Attempted synthesis of 2,2,2-trichloroethyl 16-
hydroxyhexadecanoate 
 
The NMR results indicated that dimerization or polymerization had occurred. The peak with 
the highest ppm value 173.94 ppm, in the 13C NMR spectrum indicates that the main product 
is an ester (51). The singlet peak at 4.67 ppm in the 1H NMR refers to the two protons of the 
TCE moiety, the integral of these two protons was very low, and was set to 2 because it 
should account for 2 protons, compared to the larger peaks, this indicates that the desired 
TCE-ester might be present but in a very low quantity. 
 
The triplet at 3.56 refers to the two protons α to the hydroxyl group. Since the two peaks 
mentioned refer to the same number of protons, it indicates that the rest of the 16-hydroxy 
hexadecanoate molecules have esterified. The shift value of the hydrogen α to the alcohol 
shall be about 3.50 ppm, while shift value to the corresponding hydrogen in an ester is about 
4.13 ppm (prediction done with Chem Draw Ultra 10.0). At 3.98 pmm, there is a triplet that 
accounts for 22 protons, which refers to the α protons on the alcohol side of the ester on the 
dimer. The triplet at 2.39 refers to the protons on the carbon α to the carbonyl side of the ester 
of the product.  
 
With help from Marius Standal, an LCMS of the compound was performed, which showed a 
lot of peaks showed. Among these, was the expected peak at 402 m/z, however, without the 
characteristic chlorine isotope pattern. This indicates that the desired product is not present. 
When looking at all of the ions detected by the MS, a peculiar pattern of masses was 
discovered. Nine ions were detected with 44 m/z separating each of them. The signals 
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increased in intensity from 452.5 m/z to 584.6 and 628.6, and decreased with the higher m/z 
values. The values were: 452.5 m/z (15 %), 496.5 m/z (32 %), 540.5 m/z (73 %), 584.6 m/z 
(100 %), 628.6 m/z (100 %), 672.6 m/z (66 %), 716.6 m/z (32 %), 760.6 m/z (12 %), 804.6 
m/z (4 %). No rational explanation for this pattern was found. 
 
Primary aliphatic alcohols are better nucleophiles than the alcohol of TCE due to the 
inductive effect of chlorine. Therefore the electron pair on the OH is less localized. For the 
same reason, an aromatic alcohol is a poor nucleophile related to a primary aliphatic alcohol. 
This is probably the reason to why this reaction went well with the aromatic compounds, and 
not with the aliphatic alcohol. 
 
Due to limited supplies of the main reactant, this reaction was performed in a smaller scale 
than the other reactions with TCE. However, the volume of the solvent was not reduced 
equivalently. The result was a more dilute reaction mixture than the other TCE coupling 
reactions. It is a fact that 16-OH hexadecanoic acid can react with it self. In addition, a dilute 
reaction mixture favors the intramolecular lactonization. However, when the alcohol and acid 
is separated by such a long carbon chain, it is unlikely that an intramolecular lactonization can 
occur. This usually happen when the lactone ring become a 5 or 6 membered ring. 
 
Although the synthesis was done with an excess of TCE, this reaction did not proceed as 
expected. 
 
7.2.6 Attempt of coupling 2,2,2.trichloroethyl 4-hydroxybenzoate with γ-
amino butyric acid 
 
This was meant as a model synthesis, where γ-amino butyric acid (GABA) replaced OTV 
since the molecule contains both an amino group and a carboxylic acid croup.  
 
At first, the reactants were tried to dissolve in dimethylformamide (DMF) only, with 
subsequent adding of small quantities of concentrated sulfuric acid in order to dissolve the 
reactants. A total of 182 mg sulfuric acid was needed. Ultrasound bath was also needed for 
the dissolution to take place. After the purification, recrystallization from DCM was tried in 
order to produce a powder. However, this was not successful.  
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Dimethylaminopyridine (DMAP) was added as a catalyst for the reaction to take place. EDCI 
was added when the reaction was stirred on ice bath. The EDCI is a coupling reagent that 
activates the acid. The carbonyl carbon is electron deficient and is attacked by a nucleophil. 
There are two nucleophiles in the reaction, the phenol and the amine. Since the amine was 
protonated due to the acidified solution it was a poor nucleophile and would therefore not be 
able to attack the activated acid. However, the same can be said about the phenol. For the 
phenol to be a good nucleophile, it needs a higher pH in order to be deprotonated. 
 
The isolated compound had the same retention time in HPLC as the reactant (TCE protected 
p-hydroxybenzoate). However, the main peak of the mass spectrum showed a compound 
weighing 174.1 g/mol, not correlating with any of the compounds involved. This peak lacks 
the typical chlorine isotope fragmentation and can therefore not contain any chlorine atoms. 
The peak at 147.0 is about 33 % of the size of the peak at 145. This indicates that the 145 
peak contains a chlorine atom. It has not been possible to correlate any of the masses to a 
plausible product/side product of the reaction. The desired product was not observed in the 
mass spectrum. 
 
There are mainly two reasons for the failure of this experiment. Both are related to the pH. In 
order to dissolve the reactants, the solution was acidified. First, the low pH made the phenol 
unable to do a nucleophilic attack on the acid. Secondly, the EDCI was protonated due to the 
excess of acid. This rendered the acid unable to do the nucleophilic attack on the activated 
EDCI, and hence might not activated (See the detailed mechanism in Figure 26 on page 45). 
 
 
7.2.7 Attempted protection of oseltamivir carboxylate with isonicotinyl 
 
The isonicotinyloxycarbonyl has previously been used by Veber et.al. as protection group for 
amines. The isonicotinyl p-nitrophenyl carbonate used in this synthesis was obtained from a 
colleague that previously had synthesized the compound based on the article of Veber et.al. 
(52). 1H NMR of this compound was in accordance with the structure of the compound. 
 
 
CuCl2 was added to the solution as a catalyst. It is thought that Cu2+ complexes with the 
oxygen at the carbonyl, rendering the carbonyl carbon more electropositive and therefore 
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easier to attack by a nucleophil. After the reaction, H2S is bubbled through the solution in 
order to precipitate the Cu from the solution as CuS (52). 
 
The main peak from the mass spectrum, 275.1, indicates that the isolated compound was p-
nitrophenyl carbonate [M+H]+. The 1H NMR and 13C NMR, however, was not equally 
unambiguous. The singlet at 5.38 ppm could correlate to the aliphatic protons and the 
doublets at 6.89 ppm, 7.47 ppm, 8.11 ppm and 8.31 ppm could correlate to the aromatic 
protons of p-nitrophenyl carbonate if all signals were equally big. However integrals of the 
signals at 6.89 ppm and 8.11 ppm are half the size of the other signals. The 13C NMR showed 
nine signals, which do not correlate to the p-nitrophenyl carbonate that produce only eight 
signals. 
 
The NMRs and MS were not consistent since MS indicated that one of the reagents was 
isolated, while NMR indicated otherwise. Any way, the product was not observed neither in 
MS nor NMR. It was therefore decided not to proceed with isonicotinyl as the protection 
group for the amine. 
 
7.2.8 Synthesis of 2,2,2-trichloroethyl 4-((3R,4R,5S)-4-acetamido-5-(tert-
butoxycarbonylamino)-3-(pentan-3-yloxy)cyclohex-1-
enecarbonyloxy)benzoate 
 
Since the end product could be separated from the other side products in the synthesis it was 
thought to be unnecessary to perform any purification between each reaction step. An HPLC 
of the final residue showed three of the compounds showed in Figure 31 on page 53. When 
Boc2O was added to the solution, the amines on both OTV and OTVC were protected. The 
esterification was able only to take place in the molecules that were hydrolyzed in the first 
step. The Boc protection seemed to be complete due to the fact that OTV and OTVC were not 
seen in the chromatogram after the reaction with Boc2O. 
 
The carboxylic acid of OTVC-Boc was activated by DCC. The DCC reaction was allowed to 
stir for 2 days.  
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Figure 31: The five compounds of the synthesis. Only the lower left compound was desired. 
 
The purification was done by preparative HPLC using the eluent H2O:MeOH (20:80) with 10 
milli molar (mM) HCOOH. With this eluent, the other substances were eluted first. After 30 
minutes, the compound was eluted with 100% MeOH. Since the compound is very lipophilic, 
it interacts well with the C18 material of the column. 100% MeOH was therefore needed in 
order to elute the compound. 
 
The mass spectrum showed that the title compound was isolated. The main signal was 657.2 
m/z, which correspond to the [M+Na]+, with the typical pattern for a molecule with three 
chlorine atoms. 1H NMR indicates that this compound is present. Most of the shift values 
from the spectrum correspond to the desired molecule as shown in Figure 32 on page 54. One 
of the protons does not show due to moisture in the sample. None of the signals from the 
compound lacks in the spectrum, however, there are other signals that indicates that 
impurities are present. The integral of a characteristic aliphatic proton on the ring that did not 
seem to overlap with other signals was set to one. This gave the signals from the aromatic 
protons an integral of about 5 that should have been 2, and the aliphatic protons on the ether 
had integrals of 21 that should be 6, and 25 that should be 4. As seen, the integrals do not 
correspond well to each other in the way they should. This indicates that unwanted side 
products may have formed. Since the NMR showed that the compound was not completely 
dry, and some side products may have formed, a yield of 28.2 % may be overestimated. 
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Although the reaction yielded 131 mg, just a small portion thereof was used for the NMR 
analyses. The rest was used in the subsequent experiments. The concentration was therefore 
too thin for the 13C NMR to give a reliable spectrum. 
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Figure 32: The 1H NMR shift values of the title compound showed by their respective atoms. 
 
 
7.2.9 Attempted synthesis of 4-((3R,4R,5S)-4-acetamido-5-amino-3-
(pentan-3-yloxy)cyclohex-1-enecarbonyloxy)benzoic acid 
 
The two protection groups present in the structure, are Boc and TCE. Boc is deprotected 
under acidic conditions and TCE with acid in the presence of Zn in a catalytic amount. 
Although it has been described a procedure to deprotect TCE with 90 % acetic acid, it was 
chosen to utilize concentrated acetic acid in order to reduce the risk of acid catalyzed 
hydrolysis of the ester bond in the molecule.  
 
The multiplets from 1.22 ppm to 1.92 ppm in 1H NMR indicate that the isolate contained a 
large amount of aliphatic impurities. These signals in addition to the triple triplet at 3.52 ppm 
seem to originate from dicyclohexyl urea (DCU) which is a side product after the usage of 
DCC. This was used in the previous reaction and the reaction mixture was purified by 
preparative HPLC. It is possible that DCU has coeluted with the product of this reaction. 
DCU is hardly visible in UV (at 254 nm) and can therefore not be discovered at that stage of 
synthesis. 
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This theory was confirmed by the mass spectrum. The mass of DCU is 224 g/mol and the 
mass of 225.2 m/z is therefore [M+1]+ of DCU. Traces of the title compound were not seen. 
 
The 1H NMR of the starting material showed a singlet at 1.44 ppm that referred to the protons 
of Boc. This signal is absent in this 1H NMR, which indicates that the Boc group has been 
deprotected. However, the aromatic protons and the aliphatic protons at the TCE group still 
appear, indicating that this group has not been deprotected. The odd thing is that these protons 
appear with integrals that are twice as large as the rest of the protons in OTVC molecule 
should be. This could mean that half of the TCE protected molecules has hydrolyzed in the 
ester bond between OTVC and the ligand. 
 
Five of the signals in 13C NMR may originate from DCU. These are the signals at 24.1 ppm, 
24.8 ppm, 32.8 ppm, 47.6 ppm, 157.8 ppm. This means that there is only one peak left in the 
carbonyl area (164.9 ppm), where there should be three signals. Signals from both OTVC and 
the ligand has been seen, however, all of the carbonyl signals was not seen. This is most likely 
due to a thin sample. 
 
Even though the 1H NMR did not lack any of the expected signals, MS and 13C NMR has 
indicates that the desired compound is not present. However, the compound may be present in 
small quantities. 
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7.3 Crystallographic studies 
 
At first, the crystals of oseltamivir phosphate (OTVP) and OTVC were tried to be grown by 
dissolving them in various solvents and allowing solvents to evaporate from open vials over 
night as described in Table 4 below. In most of the glasses this resulted in an amorphous 
glassy formation, while in others, crystals had grown. However, the crystals had grown in 
such a rapid manner that they grew into each other, looking almost like glass in the 
microscope. This knowledge lead to the conclusion that crystals for x-ray might be grown if 
the growing process are allowed to slow down. 
 
Table 4: Experiments with crystal growing in open vials. 
Crystal growing 
 
Experiment Compound Solvent 
1 20 mg OTVC 100 µl H2O 
2 20 mg OTVC 200 µl MeOH 
3 20 mg OTVC 300 µl EtOH + 300 µl EtOH 
4 20 mg OTVP 100 µl H2O 
5 20 mg OTVP 200 µl MeOH 
6 20 mg OTVP 600 µl EtOH + 600 µl EtOH 
 
 
Crystals of the compounds, OTV and OTVC, were then tried to be grown in a slow manner, 
allowing a liquid precipitant slowly to diffuse into the chamber where the compounds are 
dissolved in water. The precipitant must be volatile, miscible with water, and the compound 
must be insoluble in the liquid. Slow but surely, the solubility of the compound will decrease 
as more of the liquid dissolves in the water. Finally, a grain will precipitate and the compound 
will precipitate onto this corn, resulting in a crystal growing slowly. 
 
The slow crystal growing experiments were carried out as described in section 9.8 on page 75.  
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Table 5: The experiments carried out for growing crystals. 
 
Exp. No. Compound Precipitant Result 
1 ACN No crystals 
2 Ethanol No crystals 
3 Isopropanol No crystals 
4 
 
OTVC 
Acetone Crystal growth 
5 ACN Crystal growth 
6 Ethanol No crystals 
7 Isopropanol No crystals 
8 
 
 
OTVP 
Acetone No crystals 
 
 
As seen in Table 5 above, several of the most commonly used precipitants such as ethanol and 
isopopanol resulted in no precipitation, and hence no crystal growth. Acetone resulted in 
crystal growth for OTVC, but not for OTV, and vice versa for ACN. To our great surprise, 
neither ethanol nor isopropanol resulted in any crystal growth in either of the substances 
although both substances are insoluble in both precipitants. 
 
Although crystals from both OTV and OTVC were grown, they were not the appropriate size 
for achieving an x-ray from them. When crystals grow, they grow in the energetically most 
favorable manner. That is, if it takes more energy to grow in the x and y direction than it takes 
to grow in the z direction, the resulting crystals will grow long and thin. This was the case for 
both OTV and OTVC. The crystals were several µm long but were measured to be about 10 
µm thick. To be able to produce any reliably x-ray structures, the crystals must have a 
thickness of at least 30 µm. 
 
In order to grow thicker crystals it is possible to alter the growing conditions, like using 
another precipitation agent, adding different salts to the solution or altering the temperature. 
However, if salts are added to the solution, they might grow into the crystals and alter the 
conformation of the molecule studied. On the other hand, three dimensional conformation of 
the molecule might not be the same in a crystal and in the solution. This means that the 
conformation obtained from the crystal might not be the same as is present in the body. 
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8 Concluding remarks 
 
A strategy for synthesis was worked out that included the hydrolysis of OTV, protection of 
amide on OTVC with Boc, protection of the ligands acid with TCE, esterification of the 
ligand with OTVC, and finally deprotection of the protecting groups. It was first tried to 
protect the amine with isonicotinyl, but since this was unsuccessful, the amine was protected 
with Boc instead. 
 
There has been synthesized a series of protected ligands for OTVC, and one of them was 
successfully esterified with the Boc protected OTVC. However, due to lack of time, it was not 
possible to find a proper way to deprotect the two protecting groups. Further research is 
needed in this area in order to obtain these products. Since no prodrugs were obtained, no 
protein binding studies were performed either. 
 
A few attempts have been made of crystallizing OTV and OTVC, since this has not been done 
before. After two weeks, there were obtained crystals from both compounds. However, the 
crystals were too thin to produce any reliable results from the x-ray. 
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9 EXPERIMENTAL 
 
9.1 Materials 
9.1.1 Reagents 
 
Chemicals Supplier Quality 
16-hydroxy hexadecanoic acid Aldrich >98% 
2,2,2-trichloroethanol Aldrich >99% 
2-[4-(bromo-methyl)phenyl]propanoic acid Aldrich >99% 
4-amino butyric acid Koch-Light Laboratories Pure CHR 
Di cyclo carbodiimide Fluka ~99% 
Di-methyl amino pyridine Fluka >98% 
Di-tert-butyl dicarbonate Janssen Chimica >97% 
EDCI Fluka >98% 
hydrochloric acid min 32% Riedel-de Haën >32% 
isopropanol A/S Vinmonopolet  
Magnesium sulphate anhydrous Fluka >98% 
m-hydroxy benzoic acid The British Drug Houses LTD >99% 
potassium hydroxide Fluka >98% 
potassium iodine Fluka >98% 
p-toluenesulphonic acid Merck pro analysi 
RP-18 Amicon  
sodium hydrogen carbonate Aldrich >99.5% 
sodium sulphate Fluka >99.0% 
Sulphuric acid Merc 95-97% 
Zn pulverized Unknown  
 
9.1.2 Solvents 
absolutt alkohol prima Arcus  
acetic acid NMD Concentrated 
dichloromethane Fluka >99,9% 
etyl acetate Fluka >99.5% 
formic acid Merck 98-100% 
methanol Sigma-Aldrich >99.9% 
tetra hydrofurane Kebolab 99.5% 
toluene Riedel-de Haën >99.9% 
water 
Elga PureLab Maxima 
HPLC (ionexchanged, 
HPLC-grade water) 
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9.1.3 Solvents for NMR 
 
Solvents for NMR Supplier Quality 
Chloroform-d Aldrich 99.8% 
Deuterium oxide Aldrich 100 % 
Methanol d6 Aldrich >99.8% 
 
 
 
9.2 ESI-MS 
 
All ESI-MS were recorded on Waters/Micromass Q-TOF2 instrument with either positive of 
negative ionization detection mode. 
 
9.3 HPLC analysis 
 
9.3.1 Apparatus 
 
9.3.1.1 Technical details 
Autosampler:    HP G1313A 
Pump:     HP Aglient 1100 series binary pump 
Column:    C18 250 x 2 mm, 5 µ particle size, Luna, Phenomenex 
Detector:    HP G1315A Diode Array Detector 
Data acquisition and handling: HP Chemstation version.A.06.03 [509] 
 
9.3.1.2 Experimental parameters 
Column temperature:   Ambient 
Injection volume:   5 µl 
Flow rate:    0.5 ml/min 
Mobile phase:    Gradient or isocratic 
Chromatogram run time  Specified in each method 
Detection wavelength:  UV, 317 nm and 250 nm 
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9.3.2 Mobile phase for method 1 
 
Time (min) % ACN % Formic acid 
10 mM, pH 3 
Flow (ml/min) 
0 20 80 0.5 
8 80 20 0.5 
12 80 20 0.5 
14 20 80 0.5 
 
 
9.4 Preparative HPLC 
 
9.4.1 Apparatus 
 
9.4.1.1 Technical details 
 
Injector:    Manual 
Pump:     Modified HP 1050 
Column: 250 x 20 mm packed with LiChroprep®RP-18, 
25-40 µm particles 
Detector:    Labomatic Labcord-200 UV spectrometer 
 
9.4.1.2 Experimental parameters 
 
Column temperature: Ambient 
Injection volume: 5 – 10 ml 
Flow rate: 5 - 10 ml/min 
Mobile phase: Isocratic 
Detection wavelength: UV, 254 or 210 nm, ± 8 nm 
 
9.4.2 Mobile phase 
The optimum isocratic mobile phases were obtained using several volume ratios of ACN and 
formic acid solution at pH 3 on analytical HPLC. The isocratic eluent that gave satisfactory 
separation with retention times of about 6 minutes was chosen as the mobile phase. 
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9.5 NMR analysis 
All 1H and 13 C NMR analyses  were recorded on a Bruker Avance DPX 300 instrument at 
300MHz and 75 MHz respectively. All experiments were performed at 25°C with deuterated 
solvents. 
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9.6 Synthesises of the ligands 
9.6.1 Synthesis of 2,2,2-trichloroethyl 2-(4-
(hydroxymethyl)phenyl)propanoate 
 
 
OH
O
O
CCl3
Br
OH
O
OH
OH
O
Base
KI
Water
Heat
Molecular Weight:
243.10
Molecular Weight:
180.20
Molecular Weight:
311.59
Tolune
TCE
Ref lux
p-toluene
sulphonic acid
 
Figure 33 Synthesis scheme for 2,2,2-trichloroethyl 2-(4-(hydroxymetshyl)phenyl)propanoate 
 
2-(4-(Bromo methyl)phenyl)propanoic acid (0.504 g, 2.07 mmol), potassium iodine(one 
grain) and potassium hydroxide (1.125 g 20.0 mmol, 56.11 g/mol) were dissolved in water 
(10 ml), and was allowed to reflux for 20 minutes. HCl solution (12 ml 5%) was added to 
neutralize to pH 5. The water was evaporated under vacuum and the residue was dissolved in 
MeOH producing a precipitate which was filtered. MeOH was evaporated, yielding a dry 
powder (592 mg). Toluene (50 ml) was added together with TCE (0.932 g, 6.24 mmol, 149.40 
g/mol) and p-toluenesulphonic acid (1.771 g, 10.3 mmol, 172.20 g/mol). This was allowed to 
reflux for 2 hours, and stirring at room temperature over night. The solution was evaporated 
producing a dry powder (2,207 g) which was dissolved in DCM (40 ml) and washed with 3 
portions of H2O (40 ml). DCM was evaporated for 20 minutes at 80°C to remove remaining 
residues of toluene. The residue was dissolved in H2O:ACN (20:80) and purified on 
preparative HPLC with H2O:ACN (30:70) + 10 mM HCOOH as the eluent. A compound was 
isolated (214 mg) 
 
1H-NMR (300 MHz): δ 1.40 (d, 3H, J=7.2Hz), 1.45 (s, 1H), 2.16 (s, 
1H), 2.23 (s, 2H), 2.80 (s, 3H), 2.87 (s, 3H), 
3.61 (q, 1H, J=7.0Hz), 3.83 (s, 1H), 3.88 (s, 
1H), 7.09 (m, 7H), 7.95 (s, 1H) 
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13C NMR (75 MHz): δ 18.17, 19.64, 20.96,  27.37, 31.53, 36.59, 
38.96,  41.08,  44.89, 125.94, 126.41, 127.54, 
127.60, 128.76, 128.88, 128.99, 129.09, 
129.88, 130.22, 135.51, 136.53, 137.67, 
137.71, 137.84, 138.73, 139.33, 140.40, 
162.92, 179.36 
There were some overlapping signals. 
 
MS (ES+; TOF): Not done. 
 
9.6.2 Synthesis of 2,2,2-trichloroethyl 4-hydroxybenzoate 
 
OH
O O CCl3O OH
OH
HO CCl3+
p-toluene
sulphonic acid
Toluene
Reflux
Molecular Weight:
138,12
Molecular Weight:
149,40
Molecular Weight:
269,51
 
Figure 35 Synthesis of  2,2,2.trichloroethyl 4-hydroxybenzoate 
 
P-hydroxy benzoic acid (4.048 g, 29.31 mmol), TCE (12.279 
g, 82.1 mmol) and p-toluenesulphonic acid (18.890 g, 109.6 
mmol, 172.20 g/mol) were disolved in toluene (100 ml). The 
solution was refluxed in a dean-stark trap (Figure 34) for 15 
minutes. The solution was evaporated and water (100 ml) and 
DCM (100 ml) was added to the residue and the phases were 
separated and the aqueous phase was extracted twice more 
with DCM (100 ml). The DCM was evaporated, which 
resulted in a dry grey white powder (8.88 g). The powder 
was dissolved in THF. A white powder consisting of RP-18, 
three times the volume of the pre-column was added to the 
solution, and THF was evaporated. The grey white powder 
adsorbed to the RP-18 was put in a pre-column and was 
 
Figure 34 The 
equipment used for 
Dean Stark Trap 
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purified on a preparative HPLC, with an eluent consisting of 
H2O:ACN (40:60) + 10 mM HCOOH. This was done three 
times, due to the volume of RP-18. The eluent was 
evaporated, and the residue was dissolved in ACN, resulting 
in a product with the consistence and colour of honey. This 
was dissolved in DCM and evaporated, yielding a white dry 
powder (5.072 g, 18.81 mmol, 64.2 % yield, 99.3 % purity 
determined by HPLC). The retention time in HPLC was 9.8 
min. using method 1. 
 
1H NMR (300 MHz, CDCl3 ): δ 4.95 (2H, s), 6.92 (2H, d, J = 8,85 Hz), 8.05 
(2H, d, J = 8,85 Hz) 
The hydroxyl proton does not show 
 
13C NMR (75 MHz, CDCl3): 74.36 (1 C, s), 95.12 (1 C, s), 115.54 (2 C, s), 
120.99 (1 C, s), 132.60 (2 C, s), 
160.71 (1 C, s), 164.92 (1 C, s) 
 
MS (ES+; TOF):  266.9 (100%), 268.9 (95.6%), 270.9 (8.8%) 
[M + H]+, [M + H + 2]+, [M + H + 4]+ 
The percentages were measured with a ruler. 
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9.6.3 Synthesis of 2,2,2-trichloroethyl 3-hydroxybenzoate 
 
OH
O OH
CCl3HO+
OH
O O CCl3
p-toluene
sulphonic acid
Toluene
Reflux
Molecular Weight:
138,12
Molecular Weight:
149,40
Molecular Weight:
269,51
 
Figure 36 Synthesis of 2,2,2.trichloroethyl 3-hydroxybenzoate 
 
m-hydroxybenzoic acid (0.537 g, 3.88 mmol), TCE (1.524 g, 10.20 mmol) and p-
toluensulfonic acid (1.725 g, 10.02 mmol, 172.20 g/mol) were dissolved in toluene (130 ml) 
and refluxed at in a Dean Stark trap for 90 minutes. The solution was evaporated, and the 
residue was dissolved in DCM and washed with water (3*30 ml). The organic phase was 
evaporated and dissolved in a H2O:ACN (20:80 4 ml). This was applied on a preparative 
HPLC for purification, using the eluent H2O:ACN with HCOOH (30:70). The title compound 
was isolated, resulting in a white powder (0.153 g, 0.568 mmol, 14.6 % yield) 
 
1H-NMR (300 MHz, CDCl3)  δ 4.84 (s, 2H), 7.02 (ddd, 1H, J=0.9Hz, 
J=2.6Hz, J=8.2Hz), 7.24 (t, 1H, J=8.0Hz), 7.50 
(dd, 1H, J=1.6Hz, J=2.4Hz), 7.59 (dt, 1H, 
J=1.2Hz, J=7.9 Hz) 
 
13C-NMR (75 MHz, CDCl3) δ 74.58 (s, 1C), 94.83 (s, 1C), 116.60 (s, 1C), 
121.26 (s, 1C), 122.49 (s, 1C), 129.87 (s, 1C), 
130.03 (s, 1C), 155.88 (s, 1C), 165.10 (s, 1C) 
 
MS (ES+; TOF): 266.9 (100%), 268.9 (95.9%), 270.9 (10.1%) 
[M + H], [M + H + 2], [M + H + 4] 
The percentages were measured with a ruler. 
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9.6.4 Attempted synthesis of 2,2,2-trichloroethyl 16-
hydroxyhexadecanoate 
 
HO
O
O
Cl Cl
Cl
HO
O
OH
+ CCl3HO
p-toluene
sulphonic acid
Toluene
Reflux
Molecular Weight: 272,42
Molecular Weight: 403,81
Molecular Weight: 149,40
 
Figure 37 Synthesis of 2,2,2-trichloroethyl 16-hydroxyhexadecanoate 
 
16-hydroxyhexadecanoic acid (98 mg, 0.36 mmol), p-toluenesulfonic acid (141 mg, 0.818 
mmol, 172.20 g/mol) and TCE (153 mg, 1.02 mmol) were dissolved in toluene (50 ml) and 
refluxed in a dean stark trap for 90 minutes. The solution was evaporated and the residue was 
dissolved in ACN (100 ml) and extracted hexane (3*100 ml). The hexane phase was filtered, 
which yielded a white dry powder (50 mg) 
 
1H NMR:           δ 1.19 (m, 265H), 1.54 (m, 45H), 2.22 (m, 
22H), 2.33 (m, 3H,), 2.39 (m, 3H), 3.56 (t, 2H, 
J=6.6Hz), 3.98 (t, 22H), 4.67 (s, 2H) 
 
13C NMR: δ 28.31, 28.57, 29.09, 29.19, 29.20, 29.51, 
29.57, 34.34, 40.72, 64.33, 77.20, 173.94 
There were some overlapping signals 
 
MS: See discussion in section 7.2.5 on page 49. 
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9.7 Coupling of the ligands with a model substance 
 
 
9.7.1 Attempt of coupling 2,2,2.trichloroethyl 4-hydroxybenzoate with γ-
amino butyric acid 
O
O O CCl3
O
NH2OH
O O CCl3
HO
O
NH2+
Molecular Weight:
269,51
Molecular Weight:
103,12
Molecular Weight:
354,61
DMF
H2SO4
DMAP
EDCI
 
Figure 38 Attempt to synthesize 2,2,2-trichloroethyl 4-(4-aminobutanoyloxy)benzoate 
 
DMF (10 ml) was acidified with concentrated sulphuric acid (182 mg) in a 50 ml round 
bottomed flask. 2,2,2-trichloroethyl 4-hydroxybenzoate (251 mg, 0.931 mmol) and 4-
aminobutanoic acid (107 mg, 1.04 mmol) were added. The flask was stirred in ultrasound 
bath till the entire solid was dissolved. (DMAP) (One grain) was added and dissolved by 
stirring at ultrasound bath. The solution was put on an ice bath with a magnetic stirring. N-
(dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDCI) (362 mg, 1.89 mmol, 
191.7 g/mol) was added and dissolved using ultrasound bath. 5 minutes after the EDCI was 
added and dissolved, the reaction mixture was removed from the ice bath and was stirred for 
30 minutes. The HPLC showed a slight shortening of retention time using the method 1 (8.8 
minutes). An array of isocratic runs were ran on the HPLC to find the optimum eluent for the 
preparative HPLC. After evaporation of the reaction mixture, the residue was purified on 
preparative HPLC using the eluent H2O:ACN (30:70) + 10 mM HCOOH. Fraction 4 and 5 
was combined before evaporation. This resulted in a thick liquid (267 mg). 
 
MS (ES+; TOF): 145.0 (7.5 %), 147 (2.5 %) 174.1 (100 %), 
313.2 (5.6 %) 
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9.7.2 Attempted protection of oseltamivir carboxylate with isonicotinyl 
 
O
O
O
HN
O
NH3
N
O
O
O
NO2
+
O
O
O
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O
NH
O
P
O
-O
OH
OH
Molecular Weight: 410.4
Molecular Weight: 274.2
CuCl2
H2O
O
N
Molecular Weight: 447.5
 
 
 
A solution of CuCl2*2H2O (37 mg, 0.25 mmol, 147 g/mol) in water (0.65 ml) was added to a 
solution of OTV (103 mg, 0.251 mmol, 410.4 g/mol) in water (0.65 ml). The pH was adjusted 
to 9.5 with NaOH (25% aqueous solution). Isonicotinyl p-nitrophenylcarbonate (91 mg, 33 
mmol) was added and the solution was stirred at ultrasound bath. The solution changed color 
from green to blue. The solution was stirred over night at room temperature on a magnetic 
stirrer. One drop of acetic acid neutralized the solution to pH 7. The solution was filtered and 
washed with water. The solid was dissolved in ACN and was bubbled with H2S gas for 30 
minutes. The gas was obtained from a system where FeS was allowed to react with HCl (5 % 
aqueous solution). The solid was filtered of and the solvent was evaporated.  
 
1H NMR (300 MHz): δ 5.38 (s, 2H), 6.89 (d, 1H, J=9.1Hz), 7.47 (d, 
2H, J=9.1Hz), 8.11 (d, 1H, J=9.1Hz), 8.31 (d, 
2H, J=9.1Hz) 
13C NMR (75 MHz): δ 69.04, 122.57, 125.96, 126.71, 141.11, 
146.32, 153.11, 156.20, 164.48 
There were some overlapping signals 
 
MS (ES+; TOF): 157.1 (64 %), 219.1 (23 %), 275.1 (100 %), 
413.3 (3 %), 453.8, (5 %), 485.8 (6 %) 
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9.7.3 Speed of oseltamivir hydrolysis 
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Figure 39 Synthesis scheeme for the hydrolysis of OTV. 
 
OTVP (499 mg, 1.22 mmol) was dissolved in HCl (1.567 g, 25 % solution) and was stirred on 
a magnetic stirrer for 1 day. A part of the acidic OTV solution (415 mg) was neutralized with 
NaHCO3 to pH 7. A few drops of water were added to dissolve the base. The solution was 
added dropwise to a suspension of MgSO4 (11.5 g) in MeOH (100 ml) on a magnetic stirrer 
and was allowed to stir for 15 minutes. The suspension was filtered and the volume was 
reduced by evaporation to about 20 ml. A white powder precipitated during the evaporation. 
This was filtrated off before next reaction. The solution was put on ice bath and Boc2O (59 
mg 0.27 mmol) was dissolved in MeOH (2 ml) and added dropwise on magnetic stirrer. After 
5 minutes the reaction was allowed to stir in room temperature for 2 hours. 
The next day, another part of the acidic OTV solution (409 mg) was neutralized with 
NaHCO3 to pH 7. The solution was dried, filtered, evaporated and was allowed to react with 
Boc2O (56 mg, 0.26 mmol, 218.2 g/mol) as the day before. HPLC analyses were run of the 
reaction mixtures from both days. 
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9.7.4 Synthesis of 2,2,2-trichloroethyl 4-((3R,4R,5S)-4-acetamido-5-(tert-
butoxycarbonylamino)-3-(pentan-3-yloxy)cyclohex-1-
enecarbonyloxy)benzoate 
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Figure 40 Synthesis scheme for 2,2,2-trichloroethyl 4-((3R,4R,5S)-4-acetamido-5-(tert-
butoxycarbonylamino)-3-(pentan-3-yloxy)cyclohex-1-enecarbonyloxy)benzoate 
 
Oseltamivir phophate (298 mg, 0.726 mmol) was dissolved in HCl (1.016 g 25%) and was 
stirred on a magnetic stirrer for 1 day. The solution was neutralized with NaHCO3 to pH7. A 
few drops of water were added to dissolve the base. It takes about 590 mg NaHCO3 to 
neutralize 1 g 25 % HCl solution. A suspension of Na2SO4 (10 g) in MeOH (100 ml) was 
prepared. The neutralized OTV solution was added dropwise to the MeOH suspension on a 
magnetic stirrer. The suspension was filtered on a glass filter with suction and washed with 
MeOH. The solution was evaporated at 25°C till the remaining volume was about 20 ml. 
During evaporation more white powder seemed to precipitate from the solution. The 
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suspension was filtered on a paper filter in a glass funnel. Boc2O (244 mg, 1.12 mmol, 218.25 
g/mol) was dissolved in MeOH (2 ml) and added dropwise to the solution on ice bath with 
magnetic stirring. After 5 minutes on ice bath, the reaction was allowed to stir at room 
temperature over night. The solution was evaporated at 25°C and the residue was dissolved in 
DCM (20 ml). 2,2,2-trichloroethyl 4-hydroxybenzoate (202 mg, 0.750 mmol) was added and 
dissolved using ultrasound bath. The solution was allowed to cool down on ice bath. N,N-
dicyclohexylcarbodiimide (DCC) (151 mg, 0.731 mmol, 206.33 g/mol) was dissolved in 
DCM (2 ml) and added dropwise to the solution on ice bath with magnetic stirring. The 
reaction was allowed to stir for 2 days. The solution had a milky look, and was still milky 
after a filtration. The filtrate was evaporated and dissolved in ACN. The solution was still 
milky until the addition of water. A clear precipitate appeared which was filtered off and 
removed. The filtrate was evaporated at 25°C and dissolved in MeOH (2 ml) and purified on 
preparative HPLC using the eluent H2O:MeOH (20:80) with 10 mM HCOOH. After 30 
minutes, the eluent was switched to pure MeOH which eluted a substance with retention time 
12.8 minutes using method method 1. The title compound was isolated (131 mg, 0.205 mmol, 
90.1 % purity measured by HPLC, 28.2 % yield) 
 
1H-NMR (300 MHz, MeOH d6)  δ 0.92 (td, 21H, J=7.3Hz, J=10.6Hz), 1.29 (s, 
14H), 1.44 (s, 25H), 1.54 (m, 13H), 1.95 (m, 
1.4H), 1.98 (s, 6.8H), 2.39 (m, 0.91H), 2.83 
(dd, 1H, J=5.1Hz, J=17.6Hz), 3.35 (s, 5.5H), 
3.46 (m, 1.8H), 3.82 (m, 0.5H), 3.93 (dd, 0.9H, 
J=8.4Hz, J=11.1Hz), 4.21 (m, 1.62H), 5.08 (s, 
7H), 6.53 (d, 0.9H), 7.03 (m, 1.9H), 7.34 (d, 
4.8H, J=8.9 Hz), 8.11 (s, 5.4H), 8.17 (d, 5.4H, 
J=8,9 HZ), 
One proton does not show due to moisture in 
the sample. 
 
MS (ES+; TOF): 657.2 (100%), 659.2 (95 %), 661.2 (11 %) 
[M+Na]+, [M(37Cl)+Na]+ and [M(37Cl2)+Na]+ 
Respectively 
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9.7.5 Attempted synthesis of 4-((3R,4R,5S)-4-acetamido-5-amino-3-
(pentan-3-yloxy)cyclohex-1-enecarbonyloxy)benzoic acid 
O
O
O
HN
O
HN
O
O
O
O
CCl3
O
O
O
HN
O
NH2
OH
O
ZnAcetic acid
Molecular Weight:
635,96
Molecular Weight:
404,46
 
Figure 41 Synthesis scheme for 4-((3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-
enecarbonyloxy)benzoic acid 
 
Pulverized zinc (catalytic amount) was added to anhydrous acetic acid (5 ml).  2,2,2-
trichloroethyl 4-((3R,4R,5S)-4-acetamido-5-(tert-butoxycarbonylamino)-3-(pentan-3-
yloxy)cyclohex-1-enecarbonyloxy)benzoate (26 mg, 0.041 mmol) was added and the solution 
was stirred for 1 hour. The acetic acid was evaporated to about 2 ml. This was purified on 
preparative HPLC using H2O:ACN (40:60) with 10 mM HCOOH as the eluent. Fractions 7 
and 8 were combined and evaporated producing white solid (18 mg) with retention time 9.6 
using method 1 on HPLC. 
 
1H-NMR (300 MHz) : δ 0.96 (m, 21H), 1.22 (m, 50H), 1.41 (m, 46H), 
1.62 (m, 30H), 1.76 (m, 32H), 1.92 (m, 32H), 
2.04 (m, 3H), 2.10 (s, 6H), 2.47 (ddt, 2H, 
J=2.8Hz, J=10.2Hz, J=16.3Hz), 2.97 (dd, 2H, 
J=5.5Hz, J=17.4Hz), 3.52 (tt, 21H, J=4.1Hz, 
J=10.7Hz), 3.99 (dd, 2H, J=8.5Hz, J=11.2Hz), 
4.30 (q, 8H, J=7.1Hz), 5.03 (s, 2H), 6.93 (d, 
2H, J=8.9Hz and m, 2H), 7.79 (s, 2H), 8.03 (d, 
2H, J=8.9Hz), 8.14 (s, 1H) 
Experimental 
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13C NMR: δ 7.8, 8.1, 12.7, 21.4, 24.1, 24.7, 24.8, 25.2, 
27.8, 32.8, 47.6, 48.6, 60.4, 73.2, 73.6, 77.2, 
81.9, 114.5, 126.5, 131.4, 137.2, 157.8, 164.9, 
 
MS (ES+; TOF): 225.2 m/z (100 %) 
 
Experimental 
 - 75 - 
 
9.8 Crystallographic studies 
 
OTVP and OTVC (about 0.5 – 2 mg, enough to cover the bottom of the tube) was put in two 
respective tubes and dissolved in water (30 µl). The tubes were capped by wrapping parafilm 
on the top, and punctured with a thin needle. The tube containing OTVC was lowered into a 
glass containing acetone (1 ml), while the tube containing OTVP was lowered into a glass 
with ACN (1 ml), as shown in Figure 42 below.The glasses were sealed with screw caps, and 
placed in a dark place in room temperature for 2 weeks. 
 
 
 
Figure 42: Picture of the equipment used for crystal growth. The inner tube is capped with parafilm 
perforated with a needle to make a small hole. The liquid is allowed to diffuse through the small hole and 
dissolve in the water, precipitating the substance slowly onto a crystal. 
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